Quantification of amikacin and kanamycin in serum using a simple and validated LC–MS/MS method. (August 2014)

• Record Type: Journal Article
• Authors: Dijkstra, Jacob A; Sturkenboom, Marieke GG; Hateren, Kai van; Koster, Remco A; Greijdanus, Ben; Alffenaar, Jan-Willem C
• Is Part Of: Bioanalysis. Volume 6:Number 16(2014)
• Page Start: 2125
• Page End: 2133
• Publication Date: 2014-08
• Subjects: Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio.14.191
• Languages: English
• ISSNs: 1757-6180

Abstract

Background: Amikacin and kanamycin are frequently used in the treatment of multidrug-resistant TB. The current commercially available immunoassay is unable to analyze kanamycin and trough levels of amikacin. The objective was therefore to develop a LC–MS/MS method for the quantification of amikacin and kanamycin in human serum.Materials & methods: Using apramycin as internal standard, selectivity, accuracy, precision, recovery, matrix effects and stability were evaluated.Results: The presented LC–MS/MS method meets the recommendations of the US FDA with a low LLOQ of 250 ng/ml for amikacin and 100 ng/ml for kanamycin. No statistical significant difference was found between the LC–MS/MS method and the immunoassay of amikacin (Architect ® assay, p = 0.501).Conclusion: The low LLOQ of amikacin and the ability to analyze kanamycin makes the LC–MS/MS method the preferred method for analyzing these aminoglycosides.